ReviewFrontiers in immunology2025
Single-cell transcriptomics for immune profiling of cerebrospinal fluid in neurological diseases.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- The neuroimmune network in Alzheimer's and Parkinson's diseases: from mechanistic insights to biomarker-guided immunotherapies and clinical translation.Inflammopharmacology · 2026Review
- Longitudinal B Cell Receptor Repertoire Profiling of Heavy- and Light-Chain Features in Injured Rat Spinal Cord Tissue After Traumatic Spinal Cord Injury.ImmunoTargets and therapy · 2026Article
- Neurodegeneration rewires the tumor microenvironment via the neuro-immune-cancer axis.iScience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this comprehensive review, we delve into the significant body of research on single-cell transcriptomics in cerebrospinal fluid (CSF) to understand neurological diseases with autoimmune, neurodegenerative, infectious, or oncogenic origins. We thoroughly examine all published studies in these areas, with a particular focus on multiple sclerosis, Alzheimer's disease, and Parkinson's disease. For these diseases, we review findings related to immune cells that infiltrate the brain, based on postmortem brain tissue analyses and include CSF cytometry findings. Single-cell RNA sequencing (scRNA-seq), single-cell T cell receptor sequencing (scTCR-seq), and single-cell B cell receptor sequencing (scBCR-seq) are increasingly vital tools for studying CSF to understand various aspects of neurological diseases. These advanced techniques allow researchers to explore the etiopathogenesis of these conditions by identifying the roles and interactions of different immune cells. scRNA-seq provides detailed insights into the gene expression profiles of individual cells, revealing how specific cell types contribute to disease progression. scTCR-seq and scBCR-seq enable the study of clonal expansion in T and B cells, respectively, and facilitate antigen prediction, helping to uncover the nature of antigens that trigger adaptive immune responses. By integrating these technologies, scientists can define new therapeutic targets and categorize patients, leading to more personalized and effective treatments. This review highlights the promising advancements and addresses the current limitations of single-cell transcriptomics in the context of CSF and neurological diseases, setting the stage for future breakthroughs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.